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The optimal treatment of advanced sporadic Burkitt lymphoma in adults is still a matter of debate. The salu-
tary results of pediatric therapies did open the road for improving the adult outcome. Between May 1988
and March 2009, 71 consecutive patients—46 adults, 25 children—affected by Burkitt lymphoma/leukemia
were treated with the same intensive pediatric protocol alternating vincristine, adriamycine and fractionated
ciclophosphamide (phase A) with high dose methotrexate and high dose cytarabine (phase B) in four Italian
institutions. Eighty-nine per cent of patients were in Stage III–IV or had L3 leukemia. Complete remissions
were 67/71 (94.4%), 24/25 (96%) in children, and 43/46 (93.5%) in adults. Toxic deaths were 3/71 (4.2%), all in
adults. There were nine relapses (one in children, eight in adults), all but one observed early. After a median
observation of 94 months (range 23–275), the Event–Free Survival rate is 92% in children and 71.7% in
adults (P 5 0.067). The 23 more recent adults received also rituximab, without differences in outcome as
compared to patients who did not. Our experience conﬁrms that such an intensive pediatric-derived chemo-
therapy is feasible and improves the long-term outcome of adults with advanced Burkitt lymphoma. Am. J.
Hematol. 87:22–25, 2012. VC 2011 Wiley Periodicals, Inc.
Introduction
Fifty years after its description [1] the optimal treatment of
adult sporadic Burkitt lymphoma/leukemia (BL) still repre-
sents a matter of debate [2]. Standard chemotherapy such as
CHOP [3] or adult ALL regimens [4] are clearly inadequate
for treating BL, with a long term survival ranging from 0 to
30%. By contrast, the employment of intensive pediatric regi-
mens in adult patients determined better results [5–8]. The
HyperCVAD regimen, developed at the M.D. Anderson Can-
cer Center, conﬁrmed a good activity in BL patients. However,
the authors observed that patients older than 60 years clearly
had an inferior outcome, with a survival rate of only 17% [9].
The addition of Rituximab and the improvement in supportive
care measures possibly contributed to the achievement of
similar outcomes in older and younger adults [10].
In 1997, we reported a monocentric experience of 21
patients (8 adults and 13 children) treated with the inten-
sive short-term pediatric-derived chemotherapy regimen
POG 8617 [11], demonstrating that the outcome in adults
was not signiﬁcantly different than in children [12]. Fourteen
years after our original report, we present here the long-
term results of the same chemotherapy regimen employed
in a multicenter experience recruiting a larger cohort of 71
consecutive BL patients. Of note, 48% of adult patients
were older than 40 years and Rituximab was added to
chemotherapy in the more recently enrolled adult patients.
With a median follow-up of about 8.5 years, we conﬁrm
that this intensive pediatric-derived regimen is safe and
improves the outcome of adults with advanced BL.
Patients and Methods
Study population. . The study was conducted in four institutions of
the Veneto region (Northeastern Italy): University of Verona, Hematol-
ogy Unit (32 patients) and Pediatric Hematology Oncology Unit (25
patients); Treviso Hospital, Hematology Unit (nine patients) and Univer-
sity of Padua, Hematology Unit (ﬁve patients). Twenty-one patients,
eight adults, and 13 children were previously reported [12]. All previ-
ously untreated patients affected by BL or Burkitt’s leukemia were
included in the study. No upper age limit was ﬁxed, and patients were
enrolled if considered ﬁt for intensive chemotherapy treatment.
Diagnosis and clinical investigations. Three institutional Pathological
Departments (Verona, Treviso and Padua) performed and rewieved all
the diagnostic specimens. Diagnosis of BL was made on tissue sam-
ples showing the typical histological pattern of monotonous proliferation
of medium-sized cells with round nuclei, multiple basophilic paracen-
trally situated nucleoli, multiple cytoplasmic vacuoli, ‘‘starry-sky’’
appearance, extremely high proliferative tumor index (Ki-67 positive
>95%) and the presence of pan B-cell antigens and surface Ig expres-
sion, according to the criteria used at the time of patients’ enrollment.
Diagnosis of leukemia was done when more than 25% of blasts with
the same phenotypical characters were present in the bone marrow
samples or in peripheral blood. Patients underwent standard physical,
biochemical, and radiological examination, as described [12].
Treatment. All patients signed an informed consent before study
entry and were treated according to the pediatric-derived protocol POG
8617 [11], with minor modiﬁcations (see below and Fig. 1). In all centers,
the study was conducted with the approval of local ethics committees.
Cycle A consisted of sequential cyclophosphamide (300 mg/sqm i.v.
every 12 hr for 6 total doses, days 1–3), followed by vincristine (1.4
mg/sqm, days 4 and 11) and adriamycine (50 mg/sqm, day 4), without
steroids. Cycle B consisted of high dose methotrexate (1 g/sqm, contin-
uous i.v. infusion over 24 hr), followed by leucovorin rescue, and high
dose ARA-C (3 g/sqm i.v. every 12 hr for 4 total doses, days 2–3).
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Three complete cycles (3 phase A and 3 phase B alternated) were
planned for adults, four cycles for children. Elderly patients (age >65 years)
were planned to receive two cycles. For adult patients in ﬁrst complete
remission (CR) no consolidation or maintenance therapy was adopted.
CNS prophylaxis. During cycle A patients received double intratecal
(i.t.) medication (cytarabine 50 mg, methotrexate 12 mg) at days 1, 4, and
11. During cycle B, the i.t. planned for children was omitted in adults.
Supportive measures. Each cycle was administered when neutro-
phils 1 phagocyte count was over 500/lL and platelets over 100,000/
lL. In presence of active infection, the cycle was postponed. From
1994, G-CSF was routinely used in children and in adults, starting 24
hr after the end of chemotherapy infusion and stopping when neutrophil
1 phagocyte count reached 500/lL.
To prevent tumor lysis syndrome, all patients receive hydration (at
least 3,000 mL/sqm per day), oral allopurinol or i.v. rasburicase, and al-
kalinization to maintain urine pH >6.5. Furosemide was used if urine
ﬂow was inadequate.
Rituximab. Since Rituximab became available for treatment of adult
B-cell high-grade lymphomas from November 2002, the 23 most
recently enrolled adult patients received rituximab at standard dosage
(375 mg/sqm) the day before each cycle. Rituximab was omitted before
the ﬁrst cycle in patients with a high disease burden to minimize the
risk of tumor lysis syndrome. Children never received rituximab.
Stem cell transplantation. No patients received autologous or allo-
geneic bone marrow transplant in ﬁrst CR.
Criteria of response. CR was deﬁned as disappearance of all clini-
cal signs and symptoms of disease and negative imaging; normal bone
marrow (morphology, immunocytochemistry) was required. Remission
status was evaluated by clinical and/or radiological examination after
each cycle in all cases. Positron-emission tomography (PET) scan
became available only in the more recent years so it was not routinely
used to assess remission status. Therefore, we utilized the criteria of
response according to Cheson et al. [13]. When CR occurred after the
ﬁrst POG cycle (phase A 1 B), the deﬁnition of ‘‘early CR’’ was
adopted. After treatment completion all patients were regularly fol-
lowed: in particular a complete clinical and radiological (ecotomography
and CT scan) assessment was performed 4 and 12 months after the
end of chemotherapy and then a clinical evaluation was done at least
once a year.
Statistical analysis. Overall survival (OS) was calculated from the
beginning of therapy to the date of the last review (December 2010) or
death from any cause. Event-free survival (EFS) was calculated from
the date of the start of chemotherapy to the last observation without
events, relapse, or death from any cause. The probabilities of OS and
EFS were computed by the Kaplan–Meier method. The comparison
between survival curves was made by the log-rank test. The compari-
son between adults and children, and between adult patients who
received rituximab and who did not, was made by the Fisher exact test.
Results
Patients’ characteristics
The main clinical characters at diagnosis are reported in
Table I. There were no signiﬁcant differences between adult
patients enrolled before November 2002 and treated with-
out Rituximab, and patients enrolled after that time and
treated with immunochemotherapy (data not shown).
Treatment
As described above, a ﬁrst group of 10 children, enrolled
from 1988 to 1994, were planned to receive four cycles of
therapy. One patient received only 1.5 cycles and had pro-
gressive disease (PD); all the other nine children completed
the treatment. The second group comprised 15 children,
enrolled from 1994 to 2005, who were treated with three
complete POG cycles.
In the majority of adults the planned treatment was com-
pleted. The main reasons for not completing the therapy
were toxic deaths and PD (two and three patients, respec-
tively). Two patients with Stage I, non-bulky disease
received two cycles. Two patients aged >65 completed the
planned therapy: one of them is alive and disease-free after
4 years and the other died of acute myocardial infarction 5
months after completing the treatment, while in CR.
Results
Overall 67/71 (94.4%) of patients achieved the CR, 24/25
(96%) in children and 43/46 (93.5%) in adults. One child
progressed during the treatment and rapidly died. Among
adults, one patient had a early toxic death, before assess-
ment of response, and two patients did not obtained any
type of remission and died of disease.
There were no toxic deaths in children. The fatal toxic-
ities in adults were three: deaths were due to multi-organ
failure (one), bacterial pneumonia (one), and acute myocar-
dial infarction (one).
Relapses were nine, one in children and eight in adults.
All but one occurred early, with a median time to relapse of
only 4 months. One adult patient had an unexpectedly late
relapse, 9 years after diagnosis and died 14 months later
due to PD (Table II).
Time to response
Children had more rapid response, all but two (23/25,
92%) achieving early CR. One child obtained the CR after
the second cycle. In adults, 33/46 patients (71.7%) had an
early CR, 10/46 (21.7%) achieved CR after two or more
POG cycles and 3/46 (6.5%) did not obtain CR. This differ-
ence is not statistically signiﬁcant.
Stem cell transplantation
After relapse one pediatric patient received autologous
transplant and one adult underwent allogeneic stem cell
Figure 1. Protocol scheme. I.V.: intravenous. I.T.: intrathecal. *Cycle B is admin-
istered as soon as there is recovery of bone marrow function (neutrophils 1 phag-
ocyte count >500/lL and platelets >100,000/lL). **Leucovorin rescue starts 18 hr
after completing the MTX infusion and should be continued until the plasmatic
level of MTX is <0.1 lM. §Only in children.
TABLE I. Patients’ Characteristics
<15 yrs





Age years (median) 6 (3–14) 26 (17–39) 53 (41–77)
Male/female 19/6 16/8 15/7
Ann Arbor Stage III-IV 23 (92.0) NS 20 (83.3) 20 (90.1)
Bulky disease 9 (36.0) NS 13 (54.2) 9 (41.0)
Extranodal disease 22 (88.0) NS 17 (70.8) 15 (68.2)
SNC involvement 3 (12.0) NS 4 (16.7) 3 (13.6)
Leukemic presentation 4 (16.0) 0.034 10 (41.7) 10 (45.4)
Bone marrow involvement 6 (24.0) 0.044 11 (45.8) 12 (54.5)
Increased LDH serum levels 10 (40.0) 0.011 18 (75.0) 15 (68.2)
*
P value is calculated between children and adults (>15 years). There are no
differences between younger (i.e., 15–40 years) and older (>40 years) adults.
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transplant from a sibling donor. Both rapidly progressed
and died.
Survival
After a long follow-up, the EFS in children is 92% (me-
dian follow-up 157 months, range 67–275) and in adults is
71.7% (median follow-up 67 months, range 23–268), that is
not statistically different (P 5 0.067). The probability of
EFS is 75% for adults aged between 15 and 40, and
68.2% for adults older than 40 years, without statistical dif-
ference (Fig. 2).
Role of rituximab
Fifty percent of adults received Rituximab in addition to
chemotherapy. There were no differences in the probability
of CR achievement, relapse, and EFS. In particular,
the EFS is 69.6% and 73.9% for patients receiving or not
Rituximab (P 5 ns).
Discussion
This is a large series of patients who were treated homo-
geneously, independently by age, with the same pediatric-
designed protocol and observed for a very long follow-up
period.
The CR rate was very high (93.5% in adults and 96% in
children). This translated in a remarkable long-term cure
rate, with an overall EFS of 78.9% after a median follow-up
of about 8 years, without signiﬁcant differences between
children and adults. This results appear notable, since the
large majority of patients (89%) were in advanced stage or
leukemic phase. Another short intensive chemotherapy reg-
imen obtained an EFS of 72.7%, but half of patients were
in Stage I–II [8]. The results of other various short duration/
dose intensive regimens appear not superior, with EFS
ranging from 50 to 70% [6,7,14,15].
In a recent prospective clinicopathological study Mead
et al. highlighted the importance of a strict pathologic
deﬁnition of BL, based on immunophenotypic and genetic
criteria, since the 2-years PFS of patients treated with a
short intensive chemotherapy regimen (CODOX-M/IVAC) is
superior in BL than DLBCL, although without signiﬁcant dif-
ference (64% vs. 55%, respectively) [16]. Due to the long
accrual time of our study, diagnosis of BL was made
according to the diagnostic criteria used at the time of
study entry and we cannot rule out that some adult cases
could be now indicated as B-cell lymphomas, unclassiﬁed,
intermediate between DLBCL and BL. However, our study
population presented a homogeneous high-risk proﬁle and
was uniformly treated so we believe that this retrospective
experience could provide some informations about
the effectiveness of this treatment in high-risk, aggressive
B-cell lymphomas beyond the strict diagnostic deﬁnition.
Patients older than 40 years were under-represented in
the main published series, and their outcome was signiﬁ-
cantly inferior compared with younger patients. A pooled
analysis of various published trials showed that the median
OS at 2 years for all patients treated with short-duration
therapy was 71%, and for patients older than 40 years was
only 39% [17]. In our series about 50% of adults were older
than 40 years. All adult patients (aged 15–40 and >40
years) were characterized by a more unfavorable disease
than children (signiﬁcantly more frequent bone marrow
involvement and leukemic presentation): they achieved less
promptly the CR, and had a higher relapse rate. This
‘‘more unfavorable’’ adult disease appears independent of
the known reduced tolerance to chemotherapy in adults. In
fact, we observed a low toxic mortality (6.5%) in adults in
spite of the advanced disease and chemotherapy intensive-
ness, thus indicating that this intensive pediatric-derived
regimen can be safely used in adults also, if a vigorous
supportive care is provided.
The incidence of CNS involvement was not different
between children and adults and did not inﬂuence the out-
come: in particular, the probability of PFS in adults was
71.4% vs. 71.8% for patients with or without CNS disease.
It is likely that these results may be attributable to the use
of high doses of MTX and ARA-C.
Relapse was the main cause of failure. Relapses
occurred early, within a median time of 4 months from
CR achievement and tended to be more frequent in
adults. After relapse, patients were treated, according to
their performance status and clinical conditions, with a
range of options up to autologous or allogeneic stem cell
transplantation. Notably, no patient could be rescued and
death occurred in few weeks, suggesting that the out-
come of patients unresponsive to ﬁrst-line chemotherapy
is usually rapidly fatal and virtually no rescue possibilities
exist. This observation suggests that any curative effort
should be done with intensive treatment in the early
phase of the disease. In our experience, the use of stem
cell transplantation appears not to be necessary in ﬁrst
line and uneffective as rescue after relapse/progression
of the disease.
As far as Rituximab use, we failed to observe difference
in outcome according to its employment. This could depend
on the limited number of treated patients and on the retro-
spective nature of this comparison. In a study from M.D.
Anderson Cancer Center, patients who received Rituximab
had a deﬁnitely better outcome as compared with historical
controls [10]. However, the excellent results achieved in
children who never received rituximab could rise questions
about the role of rituximab in these extremely high kinetics
lymphomas, when an intensive chemotherapy is done. On
the other hand, the addition of Rituximab in adults could
improve the chemotherapy results due to their intrinsic
more unfavorable disease.
In conclusion, this multi-institutional study on a large
cohort of patients and a very long follow-up conﬁrms 14
years later our previous mono-institutional experience [12].
The results achieved in this rare aggressive lymphoma with
the present and other similar intensive regimens constitute
one of the major successes of chemotherapy. Our study
conﬁrms that a pediatric-oriented approach provides signiﬁ-
cant improvement also in adult and in ﬁt older patients.








(n 5 22) P*
Alive in CCR 56 (78.9) 23 (92.0) 18 (75.0) 15 (68.2) NS
Toxic deaths 3 (4.2) 0 1 (4.2) 2 (9.1) NS
Relapsed and
dead
12 (16.9) 2 (8.0) 5 (20.8) 5 (22.7) NS
*P value is calculated between children and adults (>15 years). There are no
differences between younger (i.e., 15–40 years) and older (>40 years) adults.
Figure 2. Event-free survival plots of the 71 patients according to their age
group.
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